These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20215640)

  • 1. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.
    Agrawal-Singh S; Koschmieder S; Gelsing S; Stocking C; Stehling M; Thiede C; Thoennissen NH; Köhler G; Valk PJ; Delwel R; Mills K; Bäumer N; Tickenbrock L; Hansen K; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2010 Jun; 115(22):4507-16. PubMed ID: 20215640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
    Gallagher RE; Moser BK; Racevskis J; Poiré X; Bloomfield CD; Carroll AJ; Ketterling RP; Roulston D; Schachter-Tokarz E; Zhou DC; Chen IM; Harvey R; Koval G; Sher DA; Feusner JH; Tallman MS; Larson RA; Powell BL; Appelbaum FR; Paietta E; Willman CL; Stock W
    Blood; 2012 Sep; 120(10):2098-108. PubMed ID: 22734072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
    Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
    Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
    Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
    Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of
    Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
    J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.
    Zimonjic DB; Pollock JL; Westervelt P; Popescu NC; Ley TJ
    Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13306-11. PubMed ID: 11087871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
    Yang X; Tan Y; Wang P; Zhang H; Zhao M; Zhao X; Wang K
    J Cell Mol Med; 2018 Dec; 22(12):6275-6284. PubMed ID: 30320491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
    He LZ; Tribioli C; Rivi R; Peruzzi D; Pelicci PG; Soares V; Cattoretti G; Pandolfi PP
    Proc Natl Acad Sci U S A; 1997 May; 94(10):5302-7. PubMed ID: 9144232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.
    Westervelt P; Lane AA; Pollock JL; Oldfather K; Holt MS; Zimonjic DB; Popescu NC; DiPersio JF; Ley TJ
    Blood; 2003 Sep; 102(5):1857-65. PubMed ID: 12750176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.